Complementary Treatment of PG2 to Improve Clinical Benefit Response and Quality of Life in Fatigue
Status:
Terminated
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to evaluate the efficacy and safety of PG2 as a complementary
treatment to conventional chemotherapy among NSCLC patients. In reference to previous
studies, "Clinical Benefit Response" and "Incidence of Grade III plus VI Neutropenia" will be
used as the primary endpoints in this study. Clinical Benefit Response is a metric
measurement including change in cancer or cancer treatment related "fatigue" which is related
to chronic fatigue syndrome (CFS), change in karnofsky performance status and change in
weight. The secondary endpoints include patient's global quality of life, and the blood
c-reactive protein level which is related to weight change, tumor response, survival time,
incidences of myelosuppression (including neutropenia, anemia and thrombocytopenia) and the
related G-CSF and antibiotics consumption.